Impact of preemptive hospitalization on health outcomes at the temporary COVID-19 hospital in Mexico City: a prospective observational study.
CALL score
COVID-19
HFNC
IMV
Mexico
SARS-CoV-2
preemptive hospitalization
pulse oximetry
temporary hospital
Journal
Therapeutic advances in infectious disease
ISSN: 2049-9361
Titre abrégé: Ther Adv Infect Dis
Pays: England
ID NLM: 101606715
Informations de publication
Date de publication:
Historique:
received:
07
06
2021
accepted:
30
07
2021
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
3
9
2021
Statut:
epublish
Résumé
In response to the evolution of the coronavirus disease 2019 (COVID-19) pandemic, the admission protocol for the temporary COVID-19 hospital in Mexico City has been updated to hospitalize patients preemptively with an oxygen saturation (SpO This prospective, observational, single-center study compared the progression and outcomes of patients who were preemptively hospitalized Preemptive hospitalization significantly reduced the requirement for oxygen therapy (odds ratio 0.45, 95% confidence interval 0.31-0.66), admission to the intensive care unit (ICU) (0.37, 0.23-0.60), requirement for invasive mechanical ventilation (IMV) (0.40, 0.25-0.64), and mortality (0.22, 0.10-0.50). Stratification by CALL score at admission showed that the benefit of preemptive hospitalization remained significant for patients requiring oxygen therapy (0.51, 0.31-0.83), admission to the ICU (0.48, 0.27-0.86), and IMV (0.51, 0.28-0.92). Mortality risk remained significantly reduced (0.19, 0.07-0.48). Preemptive hospitalization reduced the rate of disease progression and may be beneficial for improving COVID-19 patient outcomes.
Identifiants
pubmed: 34471535
doi: 10.1177/20499361211040325
pii: 10.1177_20499361211040325
pmc: PMC8404663
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20499361211040325Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The Carlos Slim Foundation funded this study. The funding source was involved in the design of the study, analysis, interpretation of data, and in writing the manuscript. The authors HGR, JLG, RSM, LAMJ, and RTC are employees of the Carlos Slim Foundation in Mexico. RRVV, RVB, LMJ, MAA, STB, RVAW, ESL, MDNO, AGR, LMBR, PEC, LERG, ACS, JBM, AGR, APC, HHB, LVA, and RARL are employed full-time by the temporary COVID-19 hospital. The authors declare no other outside funding from any other organizations and declare no further conflicts.
Références
Epidemiol Serv Saude. 2020 Jun 22;29(3):e2020233
pubmed: 32609142
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Infect Control. 2021 Feb;49(2):158-165
pubmed: 32652252
Cureus. 2020 Nov 7;12(11):e11368
pubmed: 33304701
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32474598
Swiss Med Wkly. 2020 Jul 15;150:w20316
pubmed: 32668007
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Circ Res. 2020 Sep 17;:
pubmed: 32938299
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Platelets. 2020 Jul 3;31(5):674-679
pubmed: 32367765
Drugs Aging. 2020 Dec;37(12):925-933
pubmed: 33150470
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Swiss Med Wkly. 2020 May 11;150:w20281
pubmed: 32391568